For example, Zileuton, a specific 5-Lox inhibitor, reduced amyloid beta levels and plaque deposition and the levels of insoluble and of hyperphosphorylated tau, and stabilized or improved cognitive function in animal models of Alzheimer’s disease [52–54]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.